To include your compound in the COVID-19 Resource Center, submit it here.

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

Aspen is navigating a path to the clinic through the COVID-19 crisis with its OrbiMed-led venture round

Aspen plans to bring its autologous iPS cell-based therapy into Parkinson’s disease patients while exploring the stem cell platform in new indications with a $70 million series A round led by OrbiMed Advisors.

Existing investors Arch Venture Partners, Domain Associates and Section 32 and new investors Frazier Healthcare Partners and Sam Altman also participated in the round announced

Read the full 578 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE